Outlook Therapeutics resubmits LYTENAVA Bevacizumab to FDA with a 60-day review timeline after successful appeal of prior rejection.

Jasper Therapeutics explores strategic alternatives for briquilimab program amid funding constraints and Phase 2b/3 trial execution risks.

Fulcrum discontinues pociredir for sickle cell disease following FDA's decision that PRC2 inhibitors carry equivalent malignancy risk regardless of...

Agios licenses SYK inhibitor cevidoplenib from Oscotec for ITP treatment, planning Phase 3 trials based on secondary endpoint data...

FDA accepted Roche's giredestrant NDA under Priority Review on June 2, 2026—targeting a November 2026 action date for the...

Pacira BioSciences posts record $726M revenue in 2025 while facing activist board challenge at June annual meeting.

Intravacc and Primrose Bio renew conjugate vaccine partnership to integrate CRM197 carrier protein supply with manufacturing services.

ViCentra triples manufacturing capacity ahead of German insulin pump expansion, positioning its Kaleido patch pump for scaled commercialization across...

BXCL501 reduces agitation across mild, moderate, and severe baseline cases in at-home trial, with strongest effect in severe episodes.

J&J's Phase 3 PROTEUS trial shows apalutamide before and after surgery cuts metastasis or death risk in high-risk prostate...